Can a common supplement help alcoholic cirrhosis patients live longer?

NCT ID NCT04250259

Recruiting now Disease control Sponsor: Indiana University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a supplement called SAMe can improve liver function and reduce deaths in people with alcoholic cirrhosis. About 196 adults with mild to moderate cirrhosis will take SAMe or a placebo daily for 24 months. Researchers will measure liver health, gut function, and survival rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: S-Adenosylmethionine (SAMe) supplement
What this could lead to: If it works, this could point toward a simple supplement to improve liver function and lower death risk in people with alcoholic cirrhosis.
What could go wrong: This is a phase 2 trial with 196 participants, so results are still early. SAMe is a supplement, not a strong drug, and may not show clear benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOLIC CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcoholic liver cirrhosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOLIC CIRRHOSIS

Contacts and locations

Locations

Cedars-Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States
Indiana University Hospital
RECRUITING

Indianapolis, Indiana, 46202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.